Lupin gets a go-ahead to market Blisovi – generic version Warner Chilcott’s Loestrin tablets – in U.S.

Pharma Major Lupin Limited (Lupin) has received final approvals for its Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.

Lupin said Tuesday that its US subsidiary, Lupin Pharmaceuticals Inc. will soon start promoting the product in the US.

Lupin’s Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets are the AB rated generic equivalent of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Lupin added that Loestrin Fe 1/20 had US sales of USD 139.7 million (IMS MAT September 2015) while Loestrin Fe 1.5/30 had US sales of USD 55.5 million (IMS MAT September 2015).